Treating MS is Expensive, But Cost Falls Over Time
Modelling the Cost Effectiveness of Interferon
Beta and Glatiramer Acetate in the Management of Multiple Sclerosis BMJ Volume
cost of drug treatment multiple sclerosis is high, but decreases with prolonged
treatment up to 20 years, concludes a study in this week's BMJ.
including experts from the University of Leicester, evaluated the cost
effectiveness of four drugs currently licensed for the treatment of multiple
sclerosis in the United Kingdom (three interferon betas and glatiramer acetate).
They assessed the effect of each drug against conventional management over 20
years using the best available evidence.
calculated that the cost of each year of life saved or prolonged by using any of
the four treatments ranged from £42,000 to £98,000. Price had a considerable
effect on the cost effectiveness for each drug.
authors stress, however, that uncertainty surrounding these estimates is
substantial, largely due to the unpredictability of the disease and the
difficulty in capturing all aspects of its impact on patients. Further research
to establish the true impact of these treatments would be of considerable value,
Leicester co-authors of the study are Dr Nicola Cooper and Professor Keith
Abrams of the Medical Statistics Group, Department of Epidemiology and Public
Health at the University of Leicester.
TO NEWSDESK: For
more information please contact Keith R Abrams, Professor of Medical Statistics,
Medical Statistics Group, Department of Epidemiology and Public Health,
University of Leicester, telephone +44 (0)116 252 3217, FAX +44 (0)116 252 3272,
This document has been approved by the head of department or section.